AGENUS INC
AGENNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $114.2M | $103.5M | $156.3M | $98.0M | $295.7M | $88.2M |
| Operating income | −$20.2M | −$120.5M | −$159.5M | −$179.4M | $25.7M | −$117.2M |
| Net income | −$3.1M | −$232.3M | −$257.4M | −$230.7M | −$28.7M | −$45.3M |
| Total assets | $226.8M | $226.3M | $313.9M | $413.6M | $466.0M | $214.5M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$271.1M | −$326.4M | −$160.3M | −$61.3M | $34.4M | −$203.7M |
| EPS (diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 |
| Shares out. | 25.3M | 418.9M | 332.5M | 257.2M | 204.7M | 161.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −17.7%
- Net margin
- −2.7%
- Return on equity
- 1.1%
- Return on assets
- −1.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-10.71
- Revenue growth (YoY)
- 10.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 32.7%high accruals
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Negative shareholder equity
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2025-01-13Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- Phase 2Active Not Recruitingreadout ~2025-12-05A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- Phase 2Active Not Recruitingreadout ~2027-09A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- Phase 2Active Not Recruitingreadout ~2028-02A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.3M | 6.1 | +21.2% |
| Apr 30, 2026 | 4.4M | 4.8 | +0.9% |
| Apr 15, 2026 | 4.3M | 3.1 | +1.5% |
| Mar 31, 2026 | 4.3M | 7.8 | +3.2% |
| Mar 13, 2026 | 4.1M | 8.6 | -1.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 15, 2026
- Results of operationsMay 11, 2026
- Other material eventMar 26, 2026
- Results of operationsMar 16, 2026
- Completed an acquisition or disposition · Unregistered equity sale · Regulation FD disclosureJan 16, 2026
- Director / officer changeJan 14, 2026
- Entered a material agreement · Modified shareholder rightsJan 8, 2026
- Results of operationsNov 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.